Clinical Trial Update: Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally [Phase 2]

View source ↗

Summary

Phase 2 trial comparing lyophilized versus liquid IMVAMUNE and a lower-dose intradermal liquid form for smallpox; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• IMVAMUNE (Modified Vaccinia Ankara (MVA))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Smallpox | Phase 2 | Status: COMPLETED | Results posted: 2021-01-12